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Abstract
Background: Neuroblastic tumours (NBTs) represent a heterogeneous spectrum of neoplastic
diseases associated with multiple genetic alterations. Structural and numerical chromosomal
changes are frequent and are predictive parameters of NBTs outcome. We performed a
comparative analysis of the biological entities constituted by NBTs with different ploidy status.
Methods: Gene expression profiling of 49 diagnostic primary NBTs with ploidy data was
performed using oligonucleotide microarray. Further analyses using Quantitative Real-Time
Polymerase Chain Reaction (Q-PCR); array-Comparative Genomic Hybridization (aCGH); and
Fluorescent in situ Hybridization (FISH) were performed to investigate the correlation between
aneuploidy, chromosomal changes and gene expression profiles.
Results: Gene expression profiling of 49 primary near-triploid and near-diploid/tetraploid NBTs
revealed distinct expression profiles associated with each NBT subgroup. A statistically significant
portion of genes mapped to 1p36 (P = 0.01) and 17p13-q21 (P < 0.0001), described as recurrently
altered in NBTs. Over 90% of these genes showed higher expression in near-triploid NBTs and the
majority are involved in cell differentiation pathways. Specific chromosomal abnormalities observed
in NBTs, 1p loss, 17q and whole chromosome 17 gains, were reflected in the gene expression
profiles. Comparison between gene copy number and expression levels suggests that differential
expression might be only partly dependent on gene copy number. Intratumoural clonal
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BMC Medical Genomics 2008, 1:36 http://www.biomedcentral.com/1755-8794/1/36heterogeneity was observed in all NBTs, with marked interclonal variability in near-diploid/
tetraploid tumours.
Conclusion: NBTs with different cellular DNA content display distinct transcriptional profiles
with a significant portion of differentially expressed genes mapping to specific chromosomal regions
known to be associated with outcome. Furthermore, our results demonstrate that these specific
genetic abnormalities are highly heterogeneous in all NBTs, and suggest that NBTs with different
ploidy status may result from different mechanisms of aneuploidy driving tumourigenesis.
Background
Neuroblastic tumours (NBTs) are one of the most com-
mon neoplasms in childhood, accounting for approxi-
mately 40% of solid tumours encountered in the first four
years of life [1]. NBTs are heterogeneous in terms of their
biological, genetic and morphological characteristics and
exhibit marked diverse clinical behaviours.
The biological bases of these processes are poorly under-
stood. There is an apparent link between NBTs aggressive-
ness and specific genetic aberrations (i.e., MYCN
amplification, chromosome deletions of 1p36, 11q23,
14q32 or 19q13.3; gain of 17q and near-diploid/tetra-
ploid DNA content), indicating that specific genetic alter-
ations are present in individual categories of NBTs and
likely contribute to clinical outcome [2-4].
Abnormal cellular DNA content is ubiquitous in cancer
and has been linked to the rate of cell proliferation, cell
differentiation, and prognosis in a variety of tumour cell
types. In contrast to most other tumours, hyperploidy
confers a favourable prognosis in NBTs [5], acute lym-
phoblastic leukemia [6], and rhabdomyosarcoma [7].
Non-metastatic loco-regional NBTs (stages 1, 2 and 3)
often show modal chromosomal numbers in the near-tri-
ploid range (58 to 80 modal chromosome number) and
few structural aberrations [5]. On the other hand, karyo-
types of metastatic NBTs are commonly near-diploid (44
to 57 chromosomes) or near-tetraploid (81–103 chromo-
somes) with structural changes [5].
The presence of specific and recurrent chromosomal alter-
ations in NBTs suggests that gene copy number abnormal-
ities represent a major biologically relevant event, which
contributes to NBT growth and survival. The aim of the
current study was to gain further insight into the differ-
ence in gene expression of distinct biological entities
within NBTs defined by the ploidy status.
Methods
Patients and samples
Forty-nine diagnostic primary NBT specimens (24 stages
1, 2, and 3; 7 stage 4s; and 18 stage 4) obtained from
patients diagnosed and treated at MSKCC were selected
for gene expression profiling (Table 1). Risk assessment
was defined by the INSS staging classification, the MSKCC
biological risk stratification criteria, and the COG clinical
staging criteria. NBT stages 1, 2, 3 and 4s were treated
without use of cytotoxic therapy, when possible, accord-
ing to MSKCC protocols. Stage 4 NBTs patients were
treated according to N5, N6 or N7 protocols. This study
was approved by the MSKCC and HSJD Institutional
Review Boards and informed consent was obtained before
collection of all samples.
Twenty-one samples (9 stages 1, 2, and 3; 1 stage 4s; and
11 stage 4) of the original MSKCC NBT cohort included in
the gene profiling analysis and an independent set of 25
primary NBT specimens (12 stage 1, 2, and 3, 2 stage 4s,
and 11 stage 4) obtained at diagnosis from 3 Spanish
institutions (HSJD, Barcelona; Hospital La Paz, Madrid;
and Department of Pathology, University of Valencia)
were available for validation analyses (Table 1). Normal
control DNA was obtained from the National DNA Bank
of Spain.
All tumour-specimens were evaluated by the same pathol-
ogists (WG and NP) to assess tumour cell content, only
tumours with > 70% were included in the study.
DNA content analysis
The modal DNA content was determined by flow cytome-
try DNA analysis on nuclei isolated from paraffin sections
using the method of Hedley modified [8]. DNA index
(DI) was expressed as the ratio of tumour DNA content/
standard DNA fluorescence; near-diploid DI = 0.90–1.20;
near-triploid DI = 1.21–1.75; near-tetraploid DI = 1.76–
2.20.
Gene expression profiling
Gene expression profiling was performed of 49 primary
NBT samples (22 near-triploid, 23 near-diploid and 4
near-tetraploid) using Affymetrix GeneChip Human
Genome U95 Set™ Arrays, as previously reported [9].
Microarray data and sample annotations have been
deposited in the caArray database http://caar
raydb.nci.nih.gov/caarray/.Page 2 of 15
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Case number ploidy Age INSS stage MYCN 
amplification
Disease Status Survival Status microarray 
analysis
validation 
analysis
<12m=0; 
>12m=1
1,2,3,4s=0; 4=1
1 near-3n 1 0 NA NP A Y Y
2 near-3n 1 0 NA NP A Y .
3 near-3n 1 0 NA NP A Y Y
4 near-3n 0 0 NA NP A Y .
5 near-3n 0 0 NA NP A Y Y
6 near-3n 0 0 NA NP A Y .
7 near-3n 0 0 NA P A Y .
8 near-3n 0 0 NA P A Y .
9 near-3n 0 0 NA NP A Y .
10 near-3n 0 0 NA NP A Y .
11 near-3n 1 0 NA NP A Y Y
12 near-3n 0 0 NA NP A Y .
13 near-3n 1 1 NA P D Y .
14 near-3n 1 0 NA NP A Y .
15 near-3n 0 0 NA NP A Y Y
16 near-3n 0 0 NA NP A Y .
17 near-3n 0 0 NA P A Y Y
18 near-3n 1 1 NA P D Y Y
19 near-3n 1 0 NA NP A Y .
20 near-3n 1 0 NA NP A Y Y
21 near-3n 0 0 NA P A Y .
22 near-3n 1 0 NA P D Y Y
23 near-3n 0 0 NA NP A . Y
24 near-3n 0 0 NA NP A . Y
25 near-3n 0 0 NA NP A . Y
26 near-3n 0 0 NA NP A . Y
27 near-3n 1 0 NA NP A . Y
28 near-3n 1 0 NA NP A . Y
29 near-3n 1 0 NA NP A . Y
30 near-3n 1 0 NA NP A . Y
31 near-3n 0 1 NA NP A . Y
32 near-3n 0 0 NA NP A . Y
33 near-3n 1 1 NA P A . Y
34 near-3n 0 0 NA NP A . Y
35 near-3n 0 0 NA P D . Y
36 near-3n 0 0 NA NP A . Y
37 near-3n 0 0 NA NP A . Y
38 near-2n 1 1 A NP A Y Y
39 near-2n 1 1 A P D Y Y
40 near-2n 1 0 NA P D Y .
41 near-2n 1 1 A P D Y Y
42 near-2n 1 1 A P A Y Y
43 near-2n 1 1 NA NP A Y Y
44 near-2n 1 1 NA P D Y .
45 near-2n 1 1 A P D Y .
46 near-2n 1 1 NA NP A Y .
47 near-2n 1 0 NA P D Y .
48 near-2n 1 0 NA P D Y .
49 near-2n 0 1 A NP A Y .
50 near-2n 0 0 NA NP A Y Y
51 near-2n 0 0 NA P A Y .
52 near-2n 1 1 A P D Y Y
53 near-2n 1 0 A NP A Y Y
54 near-2n 1 0 NA NP A Y .Page 3 of 15
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Genes with high variability within samples were selected
by pair-wise comparison analyses performed by adjusting
the type-I error for multiple tests (Step-down permutation
(SDP) [10], and False Discovery Rate (FDR) [11]), and
with no type-I error adjustment (Raw method). The cut-
off Family-wise error applied to select significant genes by
means of the T-test for independent data, a univariate
screening supervised procedure, was equivalent for all
three methods: < 0.1, < 0.05 and < 0.01. Hierarchical clus-
tering analyses were performed for the differentially
expressed genes for all the methods of adjustment of
Type-I error and cut-off of P-values, using a multivariate
unsupervised method, taking into account the relation-
ship between gene expressions. Fisher's exact test and 95%
bilateral confidence interval using Wilson method were
used to evaluate the proportion with which chromosomes
were represented in the selected gene sets in comparison
to chromosome representation within the Affymetrix
GeneChip U95Av2. Statistical analyses were performed
using SAS 9.1 and JMP 5.1 (SAS Institute Inc) for Win-
dows and CIA 2.1.1.
Gene Ontology annotation categories
Gene Ontology (GO) annotation categories were ana-
lyzed using explore GeneOntology (eGOn v2.0) in Gene
Tools web service http://www.genetools.no to create a bio-
logical profile of the differentially expressed genes. Over-
represented GO terms were determined statistically by
Fisher's exact test (P < 0.01) and adjusted FDR < 0.01.
Quantitative Real-time PCR (Q-PCR)
Quantification of transcript levels using Q-PCR was per-
formed of 13 genes located on chromosomes 1 and 17
(see Additional file 1). Concomitant quantification of
gene copy number was performed for a set of these genes
(see Additional file 1). MYCN gene copy number was ana-
lyzed by Q-PCR, and FISH when needed. Validation anal-
yses were performed on 46 primary NBT specimens (see
patients and samples).
Q-PCR reactions and quantification, using the ΔΔCT rela-
tive quantification method, were performed on an ABI
Prism 7000 Sequence Detection System using TaqMan®
Assay-on-Demand Gene Expression products, according
to the manufacturer's protocols (Applied Biosystems, US).
All experiments included no template controls and were
performed in duplicate and repeated twice independently.
Transcript levels were measured relative to 3 normal tissue
samples (adrenal gland, lymph node and bone marrow)
and normalized to TATA box binding protein (TBP),
hypoxantine phosphoribosyltransferase 1 (HPRT1) and
succinate dehydrogenase complex, subunit A (SDHA)
expression values. Endogenous control genes were chosen
on the basis of recent publications regarding accurate nor-
malization of real-time quantitative RT-PCR in primary
neuroblastoma [12,13]. These genes are reported within
the most stable set of endogenous control genes. Gene
copy number quantification was performed as reported
previously [14]. Gene copy number was calculated rela-
tive to placental DNA using the B-Cell maturation factor
(BCMA) as reference gene. The validity of BCMA as refer-
ence gene in our cohort of NBTs was determined by copy
55 near-2n 1 1 NA P D Y Y
56 near-2n 0 0 NA P A Y .
57 near-2n 0 0 NA NP A Y .
58 near-2n 1 1 NA P D Y .
59 near-2n 1 1 NA P D Y Y
60 near-2n 1 0 NA P D Y .
61 near-2n 0 0 NA NP A . Y
62 near-2n 1 1 NA P D . Y
63 near-2n 1 1 A P D . Y
64 near-2n 1 1 NA NP A . Y
65 near-2n 1 1 NA P D . Y
66 near-2n 0 0 A NP A . Y
67 near-2n 1 1 A P D . Y
68 near-2n 1 1 NA P A . Y
69 near-4n 1 0 NA NP A Y .
70 near-4n 0 1 A P D Y Y
71 near-4n 1 1 NA NP A Y Y
72 near-4n 0 1 NA P A Y .
73 near-4n 1 0 A P D . Y
74 near-4n 1 1 A P D . Y
MYCN amplification status: NA = not amplified, A = amplified. Disease status: NP = no disease progression, P = disease progression. Survival 
status: A = alive, D = dead. Microarray and validation analyses: Y = cases analyzed.
Table 1: Clinical and Biological characteristics of patients with Neuroblastoma evaluated according to tumour ploidy status. (Continued)Page 4 of 15
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tor sample. The ratio measured was equal to 1.0016; (tumour
DNA 1.0012 ± 0.13 SD)/(placental DNA 0.9996 ± 0.05).
Fluorescent in situ hybridization (FISH)
FISH was assayed on 4 μm sections of Tissue-Micro-Array
(TMA) of formalin-fixed paraffin-embedded NBT samples
corresponding to the validation set, and partially match-
ing the MSKCC series described above. Tissue microarrays
included only tumour areas showing > 90% of tumour
cells. Sections were washed with 2× SSC buffer and fixed
in 4% paraformaldehyde in PBS. DNA-probes, CEP 17
Alpha (Ref: 32-112017;Vysis, IL, USA) LSI p53 (Ref:30-
190008;Vysis) and/or LSI 1p36 (Ref:30-231004;Vysis),
were denatured at 73°C, 5 min., applied to tissue sections
and simultaneously denatured using the Hybridizer
(DAKO) at 90°C, 4 min. Hybridization was performed for
16 h at 37°C in a humid chamber. Slides were then
washed with Buffer post-hybridization (Master Diagnos-
tica, Granada, Spain) and stained with DAPI (6-diamid-
ino-2-phenylindole) and mounted with Vectashield H-
1000 medium (Vector). One hundred nuclei were evalu-
ated for each core. Results were recorded as percentage of
nuclei present in the sample having each probe signal pat-
tern. Cell populations < 5% of abnormal cells were not
scored as significant. Microscope Magnification ×1000.
Array comparative genomic hybridization (aCGH)
Whole genome BAC-aCGH studies were performed using
the Sanger 1 Mb clone set (kindly provided by Dr. K. Szu-
hai LUMC, The Netherlands). BAC/PAC clones were
added to increase resolution for regions of interest: full
genomic coverage clones for chromosome 17 (CHORI)
and chromosome 11 (BAC/PAC isolated DNA, kindly
provided by Dr. J. San Miguel, CIC, Salamanca), and
19q13 enriched medium-coverage set (Invitrogen, CA,
USA and kindly provided by Dr. JC Cigudosa, CNIO,
Spain). BAC DNA was extracted, amplified by DOP and
Aminolinking-PCR and spotted in triplicate onto Code-
link slides (Amersham Biosciences, GE, USA).
Tumour and reference DNA (an equimolar DNA pool
from 40 healthy donors, obtained from the Spanish
National DNA Bank) was Cy5/Cy3-dCTP (Amersham,
GE) labelled using a non-commercial Random Priming
kit composed by Random Octamers dissolved in Eppicen-
tre Exo-Minus Klenow buffer, a dNTPs mix depleted in
dCTP and Exo-Minus Klenow enzyme (Eppiocentre).
Labelled DNA was purified through Illustra G-50 Micros-
pin Columns, mixed and then precipitated along with Cot
DNA (Roche). Hybridization was performed for 48 hours
at 42°C and probe excess removed.
Imaging acquisition and data analysis
Log2 data was acquired using Axon 4000B scanner and
GenePix software. Normalization was done with GenePix
software using the mean of the median of ratios of all the
autosomal features in the array, excluding those removed
by the quality flagging scripts. Gpr files were subsequently
processed with Bioconductor packages (CRAN) incorpo-
rating scripts for removing SD > 0.2 and GenePix flagged
spots. DNA copy algorithm and Merge Levels scripts (both
implemented in snap CGH package) were applied for seg-
mentation of the data. A graded colour code adjusted to
the log2 rank of each individual plot was assigned to
define the segments found by the applied algorithm. Uni-
versal threshold cut-off values for defining gain/loss were
not applied because of subpopulation clonal heterogene-
ity, ploidy, and percentage of neuroblastic cells, which
varied from one sample to another. Due to this, plots were
evaluated independently by visual examination and
results were depicted using a graded colour code adjusted
to the log2 rank of each plot, assigning a colour grade to
every segment found by the segmentation algorithm.
Results
Differential gene expression analysis
Gene expression analysis was performed on a spectrum of
49 NBTs with varying DNA content (22 near-triploid, 23
near-diploid and 4 near-tetraploid). Owing to reduced
number of near-tetraploid cases included in this study and
taking into account the reported biological and clinical
similarities with near-diploid NBTs [15,16], near-diploid
and near-tetraploid NBTs were combined in one group.
Pair-wise comparison analyses of near-triploid (n = 22)
versus near-diploid/tetraploid (n = 27) NBTs revealed
small sets of differentially expressed genes when using a
stringent correction for multiple sampling, (6 genes [FDR
< 0.01] and 12 genes [SDP < 0.1]) (see Additional file 2).
Interestingly, all genes showing a higher expression in the
near-triploid group mapped to chromosome 17 (see
Additional file 2). Less stringent multiple testing correc-
tions selected a larger set of differentially expressed genes,
(51 genes [FDR < 0.05] (Fig. 1) and 254 genes [FDR < 0.1]
(see Additional file 2). Again, this resulted in a statistically
significant proportion of genes mapping to chromosomes
with described recurrent abnormalities in NBTs; chromo-
some 1 (p = 0.01) and chromosome 17 (p < 0.0001) (Fig.
1). Chromosomal region specificity was observed since
the majority of chromosome 1 and 17 differentially
expressed genes spread over 1p36-p22.1 and 17p13-
17q21 (Fig. 1; see Additional file 2). The majority showed
higher expression in near-triploid NBTs; 92% (CI: 78% to
97%) of chromosome 1 genes and 91% (CI: 76% to 96%)
of chromosome 17 (see Additional file 2). Only 8% (CI:
2% to 21%) probe sets for genes located on chromosome
1, ENO1 (1p36.2), CCT3 (1q23) and C1orf107 (1q32.2),
and 9% (CI: 3% to 23%) for genes on chromosome 17,Page 5 of 15
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higher expression within near-diploid/tetraploid NBTs.
The Gene Ontology biological profile of genes with higher
expression in near-diploid/tetraploid NBTs showed
enrichment for genes related to protein, macromolecular
and nucleic acid biosynthesis, such as, NME1, ATP5I,
ATP5C1, NME4, TYMS and GMPS. Whereas, near-triploid
tumours included genes involved in vesicle mediated
transport, cell communication, signal transduction, nerv-
ous system development and regulation of small GTPase
mediated signal transduction. A large portion of these
genes mapped to chromosomes 1 and 17 (60–100%),
among these RERE, CHD5, CLCN6, CDC42BPA, NTRK1,
ARHGEF11, PMP22, VAMP2, GARNL4, MAP2K4 and
FLOT2.
Quantitative Real-time Polymerase Chain Reaction (Q-
PCR)
Quantification of transcript levels of 13 differentially
expressed genes, located mainly on the chromosomal
regions 1p36 and 17p13-q21, was performed on two sep-
arate groups of NBT specimens: 21 primary NBTs from the
original MSKCC cohort as well as on an independent set
A heatmap illustrating the distinct expression profiles of 49 NB primary tumours with varying ploidy statusFigure 1
A heatmap illustrating the distinct expression profiles of 49 NB primary tumours with varying ploidy status. 
Gene expression profiles visualized according to 51 differentially expressed genes [FDR < 0.05]. (Right) Gene dendrogram is 
divided in 2 main gene clusters. Top cluster: genes displaying higher expression in near-triploid tumours; a statistically signifi-
cant proportion of genes map to chromosome 1 (p = 0.01) and chromosome 17 (p < 0.0001) (Blue). Bottom cluster: genes 
with higher expression in near-diploid/tetraploid NBTs. (Bottom) Filled in boxes: Ploidy: black = near-diploid, empty white 
boxes = near-triploid, grey = near-tetraploid NBTs; MYCN: black = amplified, white = not amplified; Age: black > 12 months, 
white < 12 months; INSS: black = Stage 4 NBTs, white = stages 1, 2, 3, and 4S.
5q32 ABLIM3 
17p12-p11.2 PMP22 
7p12-p11.2 GRB10
17p13.2 ZZEP1 
7p22 RAC1
1p34.3 PHC2
1q42.1 DISC1 
11p12-q12 ARHGAP1
1p36.3 CDC2L2 
17p13.1 POLR2A
17p11.2 TOML2
17q22-q23 TNFAIP1 
17p13.3 RUTBC1
17p11.2 EPN2
17q11.2 IFT20 
17p13.3 SKIP 
17q21.1-q21.3 EZN1 
1p36.31 CHD5 
1p36.22 CLSTN1 
1p36.33 GNB1 
17p13.3 GARNL4 
17p13.3 PAFAH1B1 
17q23-q24 RGS9 
1p36.2 TNFRSF25 
1p36.1-p36.2 RERE 
17q11-q12 FLOT2 
17p11.2 ALDH3A2 
7p11 DDC 
1q21-q22 NTRK1
19p13.2 CARM1 
5q33.3-q34 FABP6
19q12-q13.1 UQCRFS1
19q13.1 SPINT2 
Xq28 Cxorf40 
Xq27 LDOC1 
Xq28 VBP1 
16q23.3 MPHOSPH6 
14q21.1 PNN 
19p13.2 FARSLA
19p13.13 RNASEH2A 
2p22.2 CEBPZ
Xq28 SSR4 
3q24 GMPS
3q21-q23 MRPL3 
4p15.31 GPR125
12q23.1 SNRPF
1p36.3-p33.2 ENO1
5q35 NPM1 
14q11.2-q12 APEX1 
Xq25 RAB33APage 6 of 15
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PCR confirmed the microarray data in both sets of NBTs
(Fig. 2A, B and 2C).
Four genes located on chromosomes 1 and 17 were fur-
ther analyzed for gene copy number by DNA Q-PCR anal-
ysis in 27 cases (Tables 2 and 3; see Additional file 3).
Near-triploid NBTs (n = 13) showed, both for chromo-
some 1 and 17, fold values consistently higher (≥ 1.3-
fold) than normal reference gene values, and were consid-
ered to represent a minimum trisomic gene copy number.
Only case # 2 (Table 2; see Additional file 3) showed 0.8–
1.1-fold values reflecting a possible loss of 1p36, subse-
quently confirmed by FISH and aCGH results. Near-dip-
loid/tetraploid NBTs (n = 13) displayed a wider range of
values (0.5–2.7-fold), indicative of losses and gains
within a more heterogeneous clonal population, as
shown by FISH results. Tumour clonal heterogeneity may
often confound analyses performed on the bulk of the
tumour specimen and could explain some discrepancies
between ploidy and gene copy number.
Comparison between DNA gene copy number and expres-
sion levels (Fig. 3) revealed an overall linear correlation
for those analyzed genes that displayed in the microarray
analysis higher expression levels in near-triploid NBTs.
Conversely, NME1 gene, as from microarray results,
showed low expression values, closer to the disomic refer-
ence sample expression, in near-triploid NBTs, and high
fold increase in mRNA levels in near-diploid and tetra-
ploid cases.
Fluorescent in situ hybridization (FISH)
Interphase FISH using the DNA probes LSI 1p36 and LSI
1q25 was performed on 13 primary NBTs drawn from the
HSJD cohort; four cases were not evaluable (Table 2).
According to chromosome 1 status, near-triploid and
near-diploid/tetraploid NBTs were characterized by intra-
tumoural heterogeneous cell population content. Only 1
case showed uniform distribution of probe signals within
cells of the tumour specimen (case #10, Table 2). All but
one of the near-triploid NBTs were constituted of clonal
populations with two LSI 1p36 and LSI 1q25 signals (2:2)
and/or three (3:3) DNA probe signal, ranging from 40–
60% and 40–100% of the cells, respectively. Case # 2 was
the only near-triploid NBT that exhibited a chromosome
1p36 loss in 30% of cells, confirmed by aCGH and Q-
PCR. Even higher intratumoural heterogeneity was
observed in near-diploid/tetraploid NBTs.
Chromosome 17 FISH using centromeric CEP 17 and LSI
p53 (17p13.1) DNA probes, was performed on 53 pri-
mary NBTs (13 cases from the HSJD cohort, Table 3, and
40 cases from MSKCC, Table 4). Based on chromosome
17 status, near-triploid tumours were constituted of two
(2 CEP 17 and 2 LSI p53 signals, 2:2), three (3:3) and four
(4:4) chromosome 17 signals clonal populations that
ranged from 10–55%, 24–70% and 7–45% of the cells,
respectively. Near-diploid/tetraploid NBTs were com-
posed by a more heterogeneous cell population, with a
high incidence of chromosomal structural abnormalities.
In a large portion of these tumours, alongside with the
two (2:2) DNA probe signal clonal populations (6%–
100% of cells), the aneuploid cell population counterpart
constituted a significant and heterogeneous portion of cell
population (Tables 3 and 4).
Intratumoural clonal heterogeneity was observed in all
the FISH analyses (Fig. 4).
Array comparative genomic hybridization (aCGH)
Genome array CGH was performed for 13 cases, drawn
from the HSJD validation set of NBTs, with complete FISH
and Q-PCR analyses (Tables 2 and 3; Fig. 5). Near-triploid
NBTs exhibited the highest incidence of specific chromo-
somal alterations, with consistent gain or loss of whole
chromosomes, being chromosomes 7 and 17 the most fre-
quently gained (83% and 100% cases, respectively),
whilst, chromosomes 3, 4, 9, 14, 16 (50% cases), and 19
(67% NBTs) were among the most frequently lost,
although the set of cases is not large enough for statisti-
cally significant results. Chromosome 1p loss was
observed only in one case (case# 2, Table 2), a near-trip-
loid stage 4s tumour.
Specific near-diploid/tetraploid copy number alterations
were characterized by a more heterogeneous pattern of
chromosomal aberrations than those of near-triploid,
being partial chromosomal segment alterations much
more frequent than in near-triploid tumours (Fig 5; see
Additional file 4). Partial loss of 11q and partial gain of
17q were only observed in near-diploid/tetraploid sam-
ples and never in near-triploid NBTs. Chromosome 20
showed a common pattern being one of the most frequent
gains both in near-diploid and near-triploid NBTs. MYCN
amplification was absent in near-triploid cases and shared
by near-diploid/tetraploid cases.
Further copy-number alterations that did not reach the
maximum log2 values, but were clearly distinguishable in
terms of segmentation algorithm, were detected in the
array CGH plots and could reflect higher intratumoural
clonal heterogeneity (data not shown).
Discussion
Aneuploidy is ubiquitous in cancer and has been linked to
cell proliferation, cell differentiation and prognosis. The
karyotypes of most tumours are aneuploid, meaning that
chromosomes, which carry thousands of genes, are struc-
turally rearranged, duplicated, broken or entirely missing.Page 7 of 15
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Quantitative real-time PCR validation of microarray gene expression dataFigure 2
Quantitative real-time PCR validation of microarray gene expression data. Comparison of gene expression levels of 
5 representative genes located on chromosomes 1 and 17. A. Microarray gene expression data in 49 NBT from MSKCC. Gene 
expression data were log-transformed and normalized to TBP expression levels; B. Q-PCR gene transcript quantification in 21 
NBTs from MSKCC; C. Q-PCR gene transcript quantification in 25 NBTs from Spanish institutions. Results were compared by 
two-tailed independent-sample t test using SPSS v.14.0 for Windows (SPSS, Chicago, IL). Expression data are shown as box 
plots (SPSS v.14.0).
BMC Medical Genomics 2008, 1:36 http://www.biomedcentral.com/1755-8794/1/36Gain of chromosome 17 is one of the most frequent
genetic abnormalities observed in NBTs, and may involve
either the entire chromosome or partial gain of the distal
segment 17q21-qter [17]. Unbalanced translocations,
characteristic of near diploid NBTs or tumours with struc-
tural rather than numerical chromosome aberrations, are
thought to arise from DNA double strand breaks repaired
erroneously, suggesting an impaired DNA maintenance or
repair pathway [18]. On the other hand, abnormalities in
the mitotic segregation of chromosomes are thought to
underlie the numerical aberrations characteristic of near-
triploid, good prognostic, NBTs. Both mechanisms define
the type of aneuploidy behind each of the subgroups of
NBTs, determining the kind of genetic aberrations as well
as the biological behaviour of each NBT subtype.
Gene expression profiling of NBTs with different ploidy
status, near-triploid or near-diploid/tetraploid, enabled
us to identify distinct expression profiles associated with
each subgroup. Interestingly, a statistically significant pro-
portion of genes shown to be differentially expressed
mapped to chromosomes described to be recurrently
altered in NBTs, chromosomes 1 and 17 [17]. Chromo-
somal region specificity was also observed for these differ-
entially expressed genes since the majority spread
predominantly over the chromosomal regions 1p36-
p22.1 and 17p13-17q21. Besides, over 90% of these genes
displayed higher expression levels in near-triploid
tumours. Only two genes mapping to chromosome 17,
MAC30 and NME1, exhibited a higher expression level in
near-diploid/tetraploid NBTs. MAC30 gene encodes for a
meningioma-associated protein, highly expressed in sev-
eral types of tumours, but, with unknown clinicopatho-
logical and biological significance. The product of the
NME1 gene, the nm23A protein, is a nucleoside diphos-
phate kinase, whose expression has been related to cell
proliferative activity [19]. Whereas reduced expression of
NME1 is associated with a high potential for metastasis in
some tumour types, like breast cancer and melanoma, its
expression is increased in aggressive NBTs [20].
Genome array CGH, together with FISH and Q-PCR
results, confirmed the association of specific chromo-
somal abnormalities with each of the NBTs subgroups.
Therefore, it is not unreasonable to assume that these spe-
cific chromosomal alterations are associated with the
observed gene expression profiles. The highly significant
and strikingly persistent chromosomal localization of the
differentially expressed genes made us hypothesize about
which transcriptional regulation mechanisms can under-
Table 2: Results of FISH, aCGH, Q-PCR analyses of chromosome 1, displayed in relation to NBTs ploidy status
Case 
Number
Ploidy MYCN FISH Chromosome 
1
a CGH Chr. 1 Q-PCR Gene copy No. 
(fold change)
Disease 
Status
Survival 
Status
Cell % (#DNA probe 
signals: LSI 1p36: LSI 
1q25)
p cen q GNB1 
(1p36.33)
RERE (1p36.1)
1 near-3n NA n.e G G G 1.6 3.2 NP A
2 near-3n NA 50 (2:2), 20 (3:3), 15 
(1:3), 15 (2:3)
L - - 0.8 1.1 NP A
3 near-3n NA 60 (2:2), 40 (3:3) - - - 1.5 2 NP A
4 near-3n NA 5 (2:2), 95 (3:3) G G G 2.6 2.4 NP A
5 near-3n NA 40 (2:2), 60 (3:3) - - - 1.4 1.3 NP A
6 near-3n NA 50 (2:2), 50 (3:3) G G G 1.4 3 NP A
7 near-2n A n.e. L - - 0.5 2.2 P D
8 near-2n NA n.e. G G G 1.6 1.5 NP A
9 near-2n NA 95 (2:2), 5 (3:3) n.e n.e n.e 0.7 0.5 NP A
10 near-2n NA 100 (2:2) - - - 0.7 0.5 P D
11 near-2n NA 35 (2:2), 65 (1:3) n.e n.e n.e 1 2.3 P D
12 near-4n A 51 (1:2), 30 (2:2), 19 
(1:3)
- - G 0.5 0.6 P D
13 near-4n A 60 (2:2), 30 (3:3), 10 
(4:4)
- - - 1.3 2.7 P D
Thirteen representative cases drawn from the HSJD cohort analyzed by FISH, aCGH and Q-PCR of chromosome 1. n.e = not evaluable results. 
MYCN amplification status: NA = not amplified, A = amplified. Disease status: NP = no disease progression, P = disease progression. Survival 
status: A = alive, D = dead. FISH: results are displayed as percentage of cells exhibiting the observed number of DNA probe signals, and exact 
number of signals for the DNA probes used: chromosome 1 (LSI 1p36 and LSI 1q25 DNA probes) and chromosome 17(LSI 17p13.1 and CEP 17 
DNA probes). Array CGH: p and q = chromosome arms, cen. = centromeric; G = chromosome gain, L = chromosome loss. Q-PCR: gene copy 
number fold changes are determined by the ΔΔCT relative quantification method.Page 9 of 15
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BMC Medical Genomics 2008, 1:36 http://www.biomedcentral.com/1755-8794/1/36lie these gene expression patterns. As a result of aneu-
ploidy, cells possibly produce imbalanced expression of
large sets of genes that are amplified or lost. Such gross
imbalances would inevitably disrupt critical cellular cir-
cuits and destabilize regulatory pathways and cellular
structures. It has been assumed that gene dosage effects
may play a role in the pathogenesis of malignant diseases.
Variations of the transcriptome due to alterations of the
gene dosage have been described in vitro [21], in vivo [22]
and in human pathologies such as trisomies 13 and 21
[23]. In our hands, when comparing gene expression lev-
els with gene copy number of a set of differentially
expressed genes located at chromosomes 1p36 and
17q13-q21, we observed a concordance between copy
number and mean expression values in all those analyzed
genes that displayed in the microarray analysis higher
expression levels in near-triploid NBTs. In contrast, NME1
gene, as from microarray results, showed low expression
values, close to the disomic reference sample expression,
in near-triploid NBTs, and high fold increase in mRNA
levels in near-diploid/tetraploid cases. NME1 gene has
been identified as one of the MYCN targets. Correlation
between MYCN overexpression and upregulation of
NME1 expression has been reported both in NBTs and
neuroblastoma cell lines [24]. In our experience, all
MYCN amplified NBTs, displaying MYCN overexpression,
as well as near-diploid cases with increased copy number
of chromosome 17q, showed high NME1 expression lev-
els. However, NME1 overexpression was also observed in
2 near-diploid MYCN single copy cases, with low MYCN
expression and no 17q gain. This suggests that in NBTs
NME1 gene expression is only partly dependent on gene
copy number and MYCN expression, and therefore
implies the existence of other mechanisms of NME1 tran-
scriptional regulation.
Recently, we reported that clonal ploidy heterogeneity is
present in virtually every single loco-regional, near-trip-
loid NBT, and detected the existence of clonal DNA con-
tent heterogeneity and evolution [25,26]. In this report
our results underscore the clonal heterogeneity of all
NBTs, with a marked complexity in the near-diploid/tetra-
ploid tumours. Furthermore, clonal variations reflected in
the array CGH plots as copy-number alterations with var-
ying log2 values, could unveil the presence of subpopula-
tions emerged during tumour development. These cellular
subpopulations are likely to be the cause of the high cell
heterogeneity also observed in the FISH analyses. These
Table 3: Results of FISH, aCGH, Q-PCR analyses of chromosome 17, displayed in relation to NBTs ploidy status
Case 
Number
Ploidy MYCN FISH Chromosome 
17
a CGH Chr. 17 Q-PCR Gene copy No. 
(fold change)
Disease 
Status
Survival 
Status
Cell % (# DNA probe 
signals: LSI 17p13.1: 
CEP 17)
p cen q RUTBC1 
(17p13.3)
NME1 
(17q21)
1 near-3n NA n.e G G G 2.3 2.5 NP A
2 near-3n NA 45 (2:2), 55 (3:3) G G G 1.5 1.5 NP A
3 near-3n NA 45 (2:2), 55 (3:3) G G G 1.3 1.4 NP A
4 near-3n NA 30 (2:2), 70 (3:3) G G G 3.6 2.2 NP A
5 near-3n NA 50 (2:2), 50 (3:3) G G G 1.6 1.3 NP A
6 near-3n NA 50 (2:2), 50 (3:3) G G G 1.4 1.5 NP A
7 near-2n NA 5 (1:1), 80 (2:2), 10 
(3:3), 5 (4:4)
n.e n.e n.e 0.7 1.4 NP A
8 near-2n NA 33 (1:1), 66 (2:2) - - - 0.8 0.7 P D
9 near-2n A 7 (1:1), 7 (2:1), 60 (2:2), 
20 (1:2), 6 (2:3)
- - G 1.1 1.4 P D
10 near-2n NA 80 (2:2), 15 (2:3), 5 (3:3) - - G 1.2 1.5 NP A
11 near-2n NA 28 (1:1); 11 (2:1), 56 
(2:2), 5 (3:2)
n.e n.e n.e 1.1 0.9 P D
12 near-4n A 45 (2:2); 55 (3:3) - - G 1 1.4 P D
13 near-4n A 45 (2:2), 45 (3:3), 10 
(4:4)
G G G 2.2 1.9 P D
Thirteen representative cases drawn from the HSJD cohort analyzed by FISH, aCGH and Q-PCR of chromosome 17. n.e = not evaluable results. 
MYCN amplification status: NA = not amplified, A = amplified. Disease status: NP = no disease progression, P = disease progression. Survival 
status: A = alive, D = dead. FISH: results are displayed as percentage of cells exhibiting the observed number of DNA probe signals, and exact 
number of signals for the DNA probes used: chromosome 1 (LSI 1p36 and LSI 1q25 DNA probes) and chromosome 17(LSI 17p13.1 and CEP 17 
DNA probes). Array CGH: p and q = chromosome arms, cen. = centromeric; G = chromosome gain, L = chromosome loss. Q-PCR: gene copy 
number fold changes are determined by the ΔΔCT relative quantification method.Page 10 of 15
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BMC Medical Genomics 2008, 1:36 http://www.biomedcentral.com/1755-8794/1/36findings are important in emphasizing the cellular heter-
ogeneity and karyotypic complexity (aneuploidy) gener-
ally associated with malignant tumours, but need a more
detailed understanding of their significance.
Conclusion
We have found that NBTs with different cellular DNA con-
tent display specific transcriptional profiles suggesting
that near-diploid/tetraploid and near-triploid NBTs result
from two different mechanisms of aneuploidy driving
tumourigenesis. A large number of the differentially
expressed genes participate in cell differentiation path-
ways and map to specific chromosomal regions recur-
rently involved in unbalanced translocations, gains and
losses in NBTs. Our results demonstrate that these specific
genetic abnormalities are complex, heterogeneous, and
translate into a gene expression profile that defines the
biological behaviour of each type of NBT.
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probe signals, and exact number of signals for the DNA probes used: chromosome 1 (LSI 1p36 and LSI 1q25 DNA probes) and chromosome 17(LSI 
17p13.1 and CEP 17 DNA probes). Array CGH: p and q = chromosome arms, cen. = centromeric; G = chromosome gain, L = chromosome loss. 
Q-PCR: gene copy number fold changes are determined by the ΔΔCT relative quantification method.Page 12 of 15
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:36 http://www.biomedcentral.com/1755-8794/1/36responsible for patient clinico-biological database man-
agement and for microarrays studies. NKC and WLG were
involved in the drafting and revision of this manuscript.
IG and CL are responsible for the quantitative PCR exper-
iments. CM and EdA are responsible for the FISH and
aCGH analyses and were also involved with the interpre-
tation of data, draft and revision of this manuscript. ET
performed the flow cytometry DNA analysis. CL, GD, JR
and IG performed the statistical analysis and interpreta-
tion of the data derived from all the samples. HB and SA
assisted with valuable technical assistance for experiments
associated with this manuscript. All were also involved in
the drafting and revisions for this manuscript. All authors
read and approved the final manuscript.
FISH analysisigure 4
FISH analysis. Intra-tumoural cell heterogeneity, cancer cells exhibit different alterations of chromosome 17. 
FISH analysis using probes for chromosome 17 (red, LSI p53; green, CEP 17) showing different cellular populations within the 
same NBT in terms of probe signal numbers. In the panels are reported two representative NBT cases; A. near-triploid NBT; 
B. near-diploid case. Five signal cells in this sample were very rare populations (< 5%) and are not displayed in Table 3.
Array-Comparative Genomic Hybridization (aCGH) results of 13 NBTs obtained from HSJDFigure 5
Array-Comparative Genomic Hybridization (aCGH) results of 13 NBTs obtained from HSJD. Results are dis-
played according to tumour ploidy status. Chromosome alterations are visualized as a graded colour code adjusted to the log2 
rank of each individual plot assigned to define chromosomal segment alterations. Filled boxes: from orange to pink colour 
shades represent increasing chromosomal copy number gains, whereas, from light blue to dark blue colour shades indicate 
chromosome losses. White colour boxes represent no detected chromosome change. Grey colour boxes represent not eval-
uable results.Page 13 of 15
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